Must-Know Finance Concepts for Life Sciences Valuations: Good, Bad, & Most Effective
Speaker: John Selig, Co-Founder and Managing Partner, Mavericks Capital
Date/Time: Friday May 20th, 2016, 8:00-10:00 AM (PST), presentation begins at 8:30 sharp
Place: Genentech, Room 42-1E
475 East Grand Avenue
South San Francisco, 94080
Pricing: Free, but online registration is required by May 18, 2016
John advises life sciences companies on M&A, licensing and financial strategy and speaks frequently on topics in valuation, deal term benchmarking, and strategy. Additionally, he teaches the Valuation and Finance module at BIO’s Executive Management Training course for BD professionals each year, and he will be teaching the Valuation module at Stanford Medical School’s Entrepreneurship Program.
Prior to joining Mavericks, John was a Managing Director at Woodside Capital Partners, a boutique investment bank. Previously, he was a management consultant, first at Strategic Decisions Group and later at Keelin Reeds Partners, where he advised both top 20 pharma and medtech companies as well as dozens of VC-backed and small- to mid-cap life sciences companies on M&A, licensing strategies, portfolio management, valuation and strategic direction. John has extensive experience in applying licensing and M&A data to inform product strategy and provide ongoing support during deal negotiations, which has yielded market-value deal terms for dozens of assets. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.
Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP, where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa. (FINRA 24, 63, 79)
This talk will present an introduction to the key concepts and most common methodologies used to evaluate life sciences assets.
If you are an entrepreneur interested in raising financing, licensing an asset or selling your company; a private investor who wants to estimate and negotiate start-up share value; or any other professional who is active in the investing sector, you'll benefit from this overview of the key concepts used in life sciences valuation discussions.
Portfolio and program managers who iteratively perform valuation of their assets in mid to late stages of drug development will also benefit from this talk.
Topics covered include:
• The various valuation methodologies used to assign a value to life science businesses and assets
• The methodologies used in particular by pharma partners and venture capitalists
• An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value